Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations

Molecular Nutrition and Food Research

Volumn 52, Issue 7, 2008, Pages 747-754

  Markowitz, John S ^a,b   Von Moltke, Lisa L ^c   Donovan, Jennifer L ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Botanical; In vitro; Interaction; Metabolism

Indexed keywords

DRUG;

DRUG INTERACTION; DRUG THERAPY; HERB DRUG INTERACTION; HUMAN; PHYTOTHERAPY; REPRODUCIBILITY; REVIEW;

DRUG INTERACTIONS; DRUG THERAPY; HERB-DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHYTOTHERAPY; REPRODUCIBILITY OF RESULTS;

EID: 53249133266     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200700159     Document Type: Review

References (52)

1. Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Chen, G., et al., Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice, Clin. Pharmacol. Ther. 2003, 74, 121-129.
2. Bailey, D. G., Dresser, G. K., Leake, B. F., Kim, R. B., Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (oatp1A2) in grapefruit juice, Clin. Pharmacol. Ther. 2007, 81, 495-502.
3. Ioannides, C., Effect of diet and nutrition on the expression of cytochromes p450, Xenobiotica 1999, 29, 109-154.
4. Blumenthal, M., Ferrier, G. K. L., Cavaliere, C., Total sales of herbal supplements in united states show steady growth, Herbalgram 1996, 71, 64-66.
5. Blumenthal, M., Ferrier, G. K. L., Cavaliere, C., Total sales of herbal supplements in united states show steady growth, Herbalgram 2006, 71, 64-66.
6. Chavez, M. L., Jordan, M. A., Chavez, P. I., Evidence-based drug-herbal interactions, Life Sci. 2006, 78, 2146-2157.
7. Piscitelli, S. C., Burstein, A. H., Chaitt, D., Alfaro, R. M., et al., Indinavir concentrations and st. John's wort, Lancet 2000, 355, 547-548.
8. Ernst, E., Possible interactions between synthetic and herbal medicinal products. Part 1: A systematic review of the indirect evidence, Perfusion 2000, 13, 4-15.
9. Ernst, E., Possible interactions between synthetic and herbal medicinal products. Part 2: A systematic review of the direct evidence, Perfusion 2000, 13, 60-70.
10. Fugh-Berman, A., Ernst, E., Herb-drug interactions: Review and assessment of report reliability, Br. J. Clin. Pharmacol. 2001, 52, 587-595.
11. Coxeter, P. D., McLachlan, A. J., Duke, C. C., Roufogalis, B. D., Herb-drug interactions: An evidence based approach, Curr. Med. Chem. 2004, 11, 1513-1525.
12. von Moltke, L. L., Greenblatt, D. J., Schmider, J., Wright, C. E., et al., In vitro approaches to predicting drug interactions in vivo, Biochem. Pharmacol. 1998, 55, 113-122.
13. Pelkonen, O., Turpeinen, M., Uusitalo, J., Rautio, A., et al., Prediction of drug metabolism and interactions on the basis of in vitro investigations, Basic Clin. Pharmacol. Toxicol. 2005, 96, 167-175.
14. Benet, L. Z., Kroetz, D. L., Sheiner, L. B., in: Molinoff, P. B., Ruddon, R. W. (Eds.) Goodman and Gilman's Pharmacologic Basis of Therapeutics, McGraw-Hill, New York 1996.
15. Lin, J. H., Yamazaki, M., Role of p-glycoprotein in pharmacokinetics- clinical implications, Clin. Pharmacokinet. 2003, 42, 59-98.
16. DeVane, C. L., Clinical significance of drug binding, protein binding, and binding displacement drug interactions, Psychopharmacol. Bull. 2002, 36, 5-21.
17. Ruschitzka, F., Meier, P. J., Turina, M., Luscher, T. F., et al., Acute heart transplant rejection due to saint John's wort, Lancet 2000, 355, 548-549.
18. Masimirembwa, C. M., Thompson, R., Andersson, T. B., In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery, Comb. Chem. High Throughput Screen. 2001, 4, 245-263.
19. Zhu, H.-J., Wang, J.-S., Markowitz, J. S., Donovan, J. L., et al., Characterization of p-glycoprotein inhibition by major cannabinoids from marijuana, J. Pharmacol. Exp. Ther. 2006, 317, 850-857.
20. Gurley, B. J., Hagan, D. W. in: McCabe, B. J, Frankel, E. H., Wolfe, J. J. (Eds), Herbal and dietary supplement interactions with drugs, CRC Press, Boca Raton 2003, pp. 259-293.
21. Williamson, G., The use of flavonoid aglycones in in vitro model systems to test biological activities: Based on bioavailability data, is this a valid approach?, Phytochem. Rev. 2002, 1, 215-222.
22. Donovan, J. L., Crespy, V., Manach, C., Morand, C., et al., Catechin is metabolized by both the small intestine and liver of rats, J. Nutr. 2001, 131, 1753-1757.
23. Crespy, V., Morand, C., Manach, C., Besson, C., et al., Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen, Am. J. Physiol. 1999, 277, G120-G126.
24. Petri, N., Tannergren, C., Holst, B., Mellon, F. A., et al., Absorption/metabolism of sulforaphane and quercetin, and regulation of phase ii enzymes, in human jejunum in vivo, Drug Metab. Dispos. 2003, 31, 805-813.
25. Kroon, P. A., Clifford, M. N., Crozier, A., Day, A. J., et al., How should we assess the effects of exposure to dietary polyphenols in vitro?, Am. J. Clin. Nutr. 2004, 79, 1145-1151.
26. Kennedy, J. A., Matthews, M. A., Waterhouse, A. L., Changes in grape seed polyphenols during fruit ripening, Phytochemistry 2000, 55, 77-85.
27. Kallithraka, S., Garciaviguera, C., Bridle, P., Bakker, J., Survey of solvents for the extraction of grape seed phenolics, Phytochem. Anal. 1995, 6, 265-267.
28. Chen, M. L., Straughn, A. B., Sadrieh, N., Meyer, M., et al., A modern view of excipient effects on bioequivalence: Case study of sorbitol, Pharm. Res. 2007, 24, 73-80.
29. Mannel, M., Drug interactions with St John's wort: Mechanisms and clinical implications, Drug Saf. 2004, 27, 773-797.
30. Moore, L. B., Goodwin, B., Jones, S. A., Wisely, G. B., et al., St. John's wort induces hepatic drug metabolism through activation of the pregnane x receptor, Proc. Natl. Acad. Sci. USA 2000, 97, 7500-7502.
31. Perloff, M. D., von Moltke, L. L., Störmer, E., Shader, R. I., et al., Saint John's wort: An in vitro analysis of p-glycoprotein induction due to extended exposure, Br. J. Pharmacol. 2001, 134, 1601-1608.
32. Obach, R. S., Inhibition of human cytochrome p450 enzymes by constituents of st. John's wort, an herbal preparation used in the treatment of depression, J. Pharmacol. Exp. Ther. 2000, 294, 88-95.
33. Markowitz, J. S., Donovan, J. L., DeVane, C. L., Taylor, R. M., et al., Effect of St. John's wort on drug metabolism by induction of cytochrome p450 3A4 enzyme, J. Am. Med. Assoc. 2003, 290, 1500-1504.
34. Hall, S., Wang, Z., Huang, S.-M., Hamman, M., et al., The interaction between St. John's wort and an oral contraceptive, Clin. Pharmacol. Ther. 2003, 74, 525-535.
35. Venkataramanan, R., Ramachandran, V., Komoroski, B. J., Zhang, S., et al., Milk thistle, a herbal supplement, decreases the activity of cyp3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures, Drug Metab. Dispos. 2000, 28, 1270-1273.
36. Beckmann-Knopp, S., Rietbrock, S., Weyhenmeyer, R., Bocker, R. H., et al., Inhibitory effects of silibinin on cytochrome p-450 enzymes in human liver microsomes, Pharmacol. Toxicol. 2000, 86, 250-256.
37. Piscitelli, S. C., Formentini, E., Burstein, A. H., Alfaro, R., et al., Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers, Pharmacotherapy 2002, 22, 551-556.
38. Backman, J. T., Maenpaa, J., Belle, D. J., Wrighton, S. A., et al., Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation, Clin. Pharmacol. Ther. 2000, 67, 382-390.
39. Brandon, E. F., Raap, C. D., Meijerman, I., Beijnen, J. H., et al., An update on in vitro test methods in human hepatic drug biotransformation research: Pros and cons, Toxicol. Appl. Pharmacol. 2003, 189, 233-246.
40. Ward, K. W., Proksch, J. W., Levy, M. A., Smith, B. R., Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics, Drug Metab. Dispos. 2001, 29, 82-88.
41. Miguez, M.-P., Anundi, I., Sainz-Pardo, L. A., Lindros, K. O., Hepatoprotective mechanism of silymarin: No evidence for involvement of cytochrome p450 2E1, Chem. Biol. Interact. 1994, 91, 51-63.
42. Beckmann-Knopp, S., Rietbrock, S., Weyhenmeyer, R., Bocker, R. H., et al., Inhibitory effects of silibinin on cytochrome p-450 enzymes in human liver microsomes, Pharmacol. Toxicol. 2000, 86, 250-256.
43. Sridar, C., Goosen, T. C., Kent, U. M., Williams, J. A. et al., Silybin inactivates cytochromes p450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases, Drug Metab. Dispos. 2004, 32, 587-594.
44. Zhang, S., Morris, M. E., Effects of the flavonoids biochanin a, morin, phloretin, and silymarin on p-glycoprotein-mediated transport, J. Pharmacol. Exp. Ther. 2003, 304, 1258-1267.
45. Zhao, J., Agarwal, R., Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase ii enzymes: Implications in cancer chemoprevention, Carcinogenesis 1999, 20, 2101-2108.
46. Piscitelli, S. C., Formentini, E., Burstein, A. H., Alfaro, R., et al., Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers, Pharmacotherapy 2002, 22, 551-556.
47. DiCenzo, R., Shelton, M., Jordan, K., Koval, C., et al., Coadministration of milk thistle and indinavir in healthy subjects, Pharmacotherapy 2003, 23, 866-870.
48. Gurley, B. J., Barone, G. W., Williams, D. K., Carrier, J., et al., Effect of milk thistle (silybum marianum) and black cohosh (cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans, Drug Metab. Dispos. 2006, 34, 69-74.
49. Gurley, B., Gardner, S., Hubbard, M., Williams, D., et al., In vivo assessment of botanical supplementation on human cytochrome p450 phenotypes: Citrus aurantium, echinacea purpurea, milk thistle, and saw palmetto, Clin. Pharmacol. Ther. 2004, 76, 428-440.
50. Gurley, B., Swain, A., Hubbard, M., Hartsfield, F., et al., Supplementation with goldenseal (hydrastis canadensis), but not kava kava (piper methysticum), inhibits human cyp3A activity in vivo, Clin. Pharmacol. Ther. 2007, 83, 61-69.
51. Gurley, B., Gardner, S., Hubbard, M., Williams, D., et al., In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome p450 1A2, 2D6, 2E1, and 3A4/5 phenotypes, Clin. Pharmacol. Ther. 2005, 77, 415-426.
52. Kirby, B. J., Unadkat, J. D., Grapefruit juice, a glass full of drug interactions?, Clin. Pharmacol. Ther. 2007, 81, 631-633.